ライフサイエンスコーパス: cotreatment

1 els; these increases were inhibited by MG132 cotreatment.

2 FN-gamma-inducible protein decreased by Alum cotreatment.

3 trisphosphate (IP3) pool after 6 h butyrate cotreatment.

4 e therapeutic index of doxorubicin with C646 cotreatment.

5 as blocked by desferrioxamine or antioxidant cotreatment.

6 an effect that was blocked by mevalonic acid cotreatment.

7 gene expression observed only upon FICZ/UVA cotreatment.

8 -mediated gene silencing requires paclitaxel cotreatment.

9 tive DNA lesions suppressible by antioxidant cotreatment.

10 along with PEG-leptin and exendin-4 or FGF21 cotreatment.

11 hout mitochondria-targeted antioxidant (MTA) cotreatment.

12 improvements were not affected by furosemide cotreatment.

13 se changes were not attenuated by furosemide cotreatment.

14 cumulation that may be caused by bevacizumab cotreatment.

15 induced apoptosis similar to AZD8055/ABT-737 cotreatment.

16 rom undergoing apoptosis in response to drug cotreatments.

17 t (ALDOST) by using several interventions as cotreatment: a Mg2+-supplemented diet; amlodipine, a CCB

18 IFN-gamma+TNF-alpha cotreatment activated PKR, resulting in phosphorylation

19 itiation (74.2%) or who started tuberculosis cotreatment after ART initiation (51.6%; P < .001).

20 TCDD cotreatment also reduced EE-mediated stromal edema, hype

21 The DMF cotreatment ameliorated CsA-induced renal dysfunction as

22 hemostatic system is activated after LPS/RAN cotreatment and that fibrin deposition in liver is impor

23 using an alkaline comet assay (+/-z-VAD-fmk cotreatment) and by levels of iododeoxyuridine-DNA incor

24 and CD8+ alphabeta T cells after HMBPP/IL-2 cotreatment as well as substantial perforin expression b

25 94.8%) than were children who were receiving cotreatment at ART initiation (74.2%) or who started tub

26 Spiro cotreatment attenuated (P<0.05) urinary and fecal Ca2+ a

27 Moreover, Src/Chk1-inhibitor cotreatment attenuated MM-cell production of vascular en

28 Spi cotreatment attenuated the rise in intracellular Ca2+, t

29 Proteasome inhibitor cotreatment blocked the induction of alpha-SMA mRNA, the

30 human epidermal tissue reconstruct, FICZ/UVA cotreatment caused pronounced phototoxicity inducing ker

31 DHA and butyrate cotreatment compared with untreated cells increased the

32 hin ovaries was achieved during chemotherapy cotreatment, concomitant with preservation of primordial

33 number, LC3II, and SQSTM1 accumulation; Tat cotreatment diminished this effect.

34 accumulated in the lung following HMBPP/IL-2 cotreatment displayed an effector memory phenotype, as f

35 HMBPP/IL-2 cotreatment during acute SHIV infection did not prevent

36 In contrast, HMBPP/IL-2 cotreatment during chronic infection did not exacerbate

37 nic loads were not increased upon HMBPP/IL-2 cotreatment during chronic SHIV infection, HMBPP activat

38 in other contexts, it may prove useful as a cotreatment for augmenting tumor Ag expression during im

39 Cotreatment for tuberculosis reduced viral suppression.

40 lity, reduced metabolic toxicity, simplified cotreatment for tuberculosis, and preservation of second

41 2272 (about 10-fold versus about 2-fold) and cotreatment had a synergistic effect, increasing cyclic

42 apoptosis and cytotoxicity after 24 hours of cotreatment in cell lines and in fresh myeloma cells, an

43 d PIT1 silencing and were mitigated by FGF23 cotreatment in HAoSMCs.

44 d genes were significantly modulated by TCDD cotreatment, indicating a gene-specific inhibitory respo

45 mostly prevented by N-acetyl cysteine (NAC) cotreatment, indicating a major role of oxidative stress

46 In A549 xenografts, brusatol and cisplatin cotreatment induced apoptosis, reduced cell proliferatio

47 rylation of IGF-I receptor (IGF-IR), whereas cotreatment induced synergistic phosphorylation and asso

48 Cotreatment-induced apoptosis was accompanied by enhance

49 us underscoring the critical role of RIP1 in cotreatment-induced apoptosis.

50 TCDD cotreatment inhibited EE-induced uterine wet weight by 3

51 Furthermore, IL1Ra/anakinra cotreatment inhibited ricin-mediated inflammatory respon

52 Surprisingly, we find that rapamycin cotreatment inhibits 6-TG-induced autophagy in MMR-profi

53 O(2) following hydrogenation and nitridation cotreatment is significantly higher than that of the sam

54 Importantly, BV6/dexamethasone cotreatment is significantly more effective than monothe

55 Hormone cotreatment led to an increased lesion severity, indicat

56 ned IRAK1 and BCL2 inhibitors and found that cotreatment more effectively eliminated MDS clones.

57 Adiponectin and leptin cotreatment normalizes insulin action in lipoatrophic in

58 gene expression studies in PC-3 cells after cotreatment of 1alpha,25(OH)2D3 plus TSA after 6 h.

59 genes and cDNA microarray analyses revealed cotreatment of 1alpha,25(OH)2D3 plus TSA cooperatively u

60 ath that was reduced to 19.87 +/- 3.03% with cotreatment of 250 nM MK-801.

61 Sepsis with cotreatment of antibiotics and antisense oligonucleotide

62 Sepsis with cotreatment of antibiotics and mismatch oligonucleotides

63 Cotreatment of BEZ235 with DOX resulted in dose-dependen

64 PGE(2), production, was potentiated with the cotreatment of BMDM with H(2)O(2).

65 Interestingly, cotreatment of BMPCs or cell lines with DSB/R inhibitors

66 Cotreatment of bone marrow B cells with 15d-PGJ(2) and M

67 Cotreatment of BRAF-mutated melanoma cell lines with phe

68 Cotreatment of breast cancer cell lines with HDAC inhibi

69 Cotreatment of C57BL/6 with AQ and anti-CTLA4 also resul

70 orylation, and CB1 internalization following cotreatment of CB1 agonist and D2 antagonist were quanti

71 Cotreatment of cells with a selective PPARgamma antagoni

72 d dephosphorylation of IRS-2 is prevented by cotreatment of cells with insulin, (Q3A4Y15L16) IGF-I, o

73 reshly isolated breast cancer cells, whereas cotreatment of cells with tamoxifen or a small molecule

74 Cotreatment of cells with the activating anti-Fas antibo

75 Notably, cotreatment of chemotherapeutic agent camptothecin enhan

76 2-M and augments cell cycle dysregulation on cotreatment of doxorubicin and caffeine.

77 Our findings indicated that cotreatment of drug-resistant neuroblastoma cells with d

78 Remarkably, cotreatment of endothelial cells with simvastatin, a hyd

79 We found that IL-4 and retinoic acid (RA) cotreatment of GM-CSF-differentiated IDCs synergisticall

80 Cotreatment of hepa1c1c7 cells with 2,3,7,8-tetrachlorod

81 id, that is further activated as verified by cotreatment of HepG2 cell lysates with (2E)-hexadecenal

82 Cotreatment of HepG2 cells with 4-HNE and the phosphatid

83 Cotreatment of Jurkat cells with marginally toxic concen

84 Cotreatment of K562 cells with 250 nM imatinib mesylate

85 Cotreatment of K562 or LAMA cells with subtoxic or margi

86 milarly, in a xenograft model the preemptive cotreatment of lung tumor cells with an EGFR inhibitor a

87 essed the synergistic cytotoxicity seen with cotreatment of luteolin and TNF.

88 Our data show that cotreatment of M. tuberculosis infected rabbits with the

89 Cotreatment of melanomas with BRAF inhibitors and obatoc

90 Cotreatment of melanomas with DCA and elesclomol in vivo

91 Cotreatment of MPA with IFN-alpha resulted in additive e

92 Cotreatment of nonprimed macrophages with ATP and calciu

93 Cotreatment of PD-1(-/-) mice with anti-CTLA4 antibody a

94 In vitro cotreatment of PROM1-expressing Mat1a-/- hepatic progeni

95 Cotreatment of rats with lipopolysaccharide from the pho

96 ction of CYP1A1 and CYP1B1 was observed with cotreatment of SRM 1649a and BP.

97 ween CB1 and D2L were observed using BRET(2) Cotreatment of STHdh(Q7/Q7) cells with ACEA and haloperi

98 cular region of the hypocotyl in response to cotreatment of Suc and sulfonamide, yet no change in aux

99 Cotreatment of T cells with N-acetylcysteine and BSO fai

100 Cotreatment of these cAMP-PDE inhibitors in naive mice w

101 Cotreatment of these mice with ultra-low-dose naltrexone

102 itro analyses: TMZ + p53 inhibitor precursor cotreatment of three distinct p53(wt) GBM xenografts res

103 fect involving hydrogenation and nitridation cotreatment of TiO(2) nanowire (NW) arrays that improves

104 and reactivation of apoptosis in vivo after cotreatment of TNF with a V-ATPase inhibitor.

105 Cotreatment of U937 cells with PD184352 and UCN-01 resul

106 Cotreatment of VPA with 5-azaC in cells almost completel

107 Ps are likely to cooccur at infection sites, cotreatments of cellobiose with flg22 or chitooligomers

108 the synergistic effects of IFN-gamma and MDP cotreatment on adhering and infiltrating cells.

109 ergistic activity of cetuximab and erlotinib cotreatment on growth inhibition of colon cancer cell li

110 sm of action, the effect of DHA and butyrate cotreatment on intracellular Ca2+ homeostasis was examin

111 RA; however, TLR4 activation was affected by cotreatment only.

112 ACEA and haloperidol cotreatments produced a delayed and sustained increase i

113 ) under these conditions, SAHA and cisplatin cotreatment promoted focal accumulation of the low-fidel

114 reconditioned group with PVE and CD133+ BMSC cotreatment (PVE+SC group, n = 11) and a group pretreate

115 ulinization of behavior by ACPD plus kainate cotreatment; rather, the coadministration of NBQX plus L

116 pression seen in MiaPaca2 cells, BEZ and DOX cotreatment reduced BIM expression in H9C2 cardiomyocyte

117 rise in plasma potassium induced by CA, Ucn2 cotreatment reduced potassium concentrations.

118 Cotreatment reduced tumor burden and improved survival.

119 Ucn2 cotreatment reversed CA-induced rises in circulating ald

120 el thromboembolic stroke model in mice, this cotreatment significantly improved ischemic lesion size

121 Moreover, BEZ cotreatment significantly improved the effects of DOX to

122 PD98059 cotreatment significantly inhibited SDF-1alpha-induced N

123 or cancer cell survival and identifies novel cotreatment strategies to override this survival advanta

124 These findings reveal a novel cotreatment strategy for tumors displaying mesenchymal f

125 iver injury induced by polyI:C/posthalothane cotreatment, suggesting that the increased hepatocyte ap

126 as well as survival analysis (P < 0.001 for cotreatment survival benefit in each case).

127 nterestingly, we found that leptin and IGF-I cotreatment synergistically transactivated epidermal gro

128 Remarkably, these cotreatments synergistically triggered mono-ubiquitinati

129 -induced Cbl tyrosine phosphorylation) by GH cotreatment; the GH effect on EGF-induced Cbl tyrosine p

130 est that calcitonin could be used as a novel cotreatment to augment efficacy and reduce side effects

131 f DSF, which we propose may be diminished by cotreatment to decrease adventitious Cu.

132 ponse, particularly in settings of sorafenib cotreatment to enhance anticancer responses.

133 induced EGFR downregulation when PRL and EGF cotreatment was compared to EGF treatment alone.

134 ubstantial disruption of neuronal processes; cotreatment with (+)-PTZ revealed marked preservation of

135 Cotreatment with 17-AAG and PKC412 markedly down-regulat

136 Cotreatment with 17-AAG and SAHA also induced down-regul

137 Cotreatment with 17-AAG and SAHA or SB synergistically i

138 Cotreatment with 17-AAG and siRNA to HDAC6 induced more

139 In addition, cotreatment with 17-AAG and tubacin augmented the loss o

140 to at least 24 h and is further decreased by cotreatment with 2-methylthio-ATP.

141 for 1 hour with (+)-PTZ followed by 18-hour cotreatment with 25 microM Glu and (+)-PTZ showed a mark

142 ce was also potentiated in nonmutant mice by cotreatment with a 5-HTT antagonist.

143 Cotreatment with a beta2-adrenergic receptor antagonist,

144 ect of chronic C3 exposure can be blocked by cotreatment with a C3aR antagonist and by genetic deleti

145 Cotreatment with a canonical Wnt signaling inhibitor att

146 antigens were significantly decreased after cotreatment with a caspase inhibitor (P<0.05) and were a

147 Cotreatment with a histone deacetylase inhibitor (an ind

148 of both uptake and biosynthesis pathways by cotreatment with a liver X receptor agonist further augm

149 Cotreatment with a low subanalgesic dose of kelatorphan,

150 nografts highly amenable to sensitization by cotreatment with a miR-139-5p mimetic.Significance: The

151 Cotreatment with a panel of Ca2+-modulating agents ident

152 Since cotreatment with a PPARbeta/delta ligand and various mit

153 to be Top2beta-dependent and preventable by cotreatment with a proteasome inhibitor, suggesting the

154 this decrease could be partially rescued by cotreatment with a proteasome inhibitor.

155 alpha can be switched to apoptosis either by cotreatment with a protein synthesis inhibitor, cyclohex

156 Cotreatment with a retinoid X receptor alpha ligand, 9-c

157 Neuroprotection was abrogated upon cotreatment with a sGC inhibitor, ODQ, thus supporting a

158 either dominant-negative mutant (DN-JNK) or cotreatment with a specific JNK inhibitor SP600125, abro

159 es were added into the media without or with cotreatment with Abeta12-28P, which is a nontoxic peptid

160 Cotreatment with ACE-536 and EPO produced a synergistic

161 Cotreatment with agents that elevate cAMP in BCECs preve

162 However, cotreatment with alcohol and LPS reduced both PPRE bindi

163 As compared with either agent alone, cotreatment with AMN107 and LBH589 induced more loss of

164 ells to panobinostat as well as suggest that cotreatment with an anti-Bcl-2 agent would augment the a

165 Therefore, cotreatment with an AR antagonist, bicalutamide, blocked

166 Cotreatment with an estrogen receptor (ER) antagonist in

167 Cotreatment with an inhibitor of peroxisome proliferator

168 Ucn2 cotreatment with an MRA in HF further improved hemodynam

169 In fact, cotreatment with an NO-peroxynitrite scavenger revealed

170 ti-CD4 mAb-induced apoptosis is inhibited by cotreatment with anti-CD8 mAb and responsiveness to irre

171 ddition of cytokines or growth factors or by cotreatment with antiandrogens.

172 tential (MMP) in Panc1 and L3.6pL cells, and cotreatment with antioxidants (glutathione and dithiothr

173 y turbulent shear stress can be prevented by cotreatment with antioxidants and l-arginine.

174 duce reactive oxygen species generation, and cotreatment with antioxidants did not alter erlotinib-in

175 Cotreatment with ascorbate and JQ1 induced apoptosis and

176 However, cotreatment with ATRA reduces Bcl6 expression to baselin

177 ous atRA concentrations and may be useful as cotreatment with atRA to combat therapy resistance.

178 e cytokine release was inhibited by pre- and cotreatment with ATRA; however, TLR4 activation was affe

179 Compared with each agent alone, cotreatment with BA and ibrutinib markedly improved the

180 Cotreatment with BA and panobinostat (pan-histone deacet

181 Cotreatment with BA and the BTK inhibitor ibrutinib syne

182 Cotreatment with BH4 prevented NOS3 uncoupling and inhib

183 Cotreatment with both agents increased the number of tra

184 ing SC104 treatment of colorectal cells, and cotreatment with caspase inhibitors has been shown to in

185 bility, and activation of apoptosis, whereas cotreatment with chloroquine or knockdown of Atg7, but n

186 These effects can be prevented by cotreatment with cholesterol and sphingomyelin, and can

187 Cotreatment with CHX and TCDD caused superinduction of C

188 ed hepatoma 1c1c7 cultures was suppressed by cotreatment with CHX.

189 Finally, cotreatment with clenbuterol and recombinant human IGF1

190 +) and CD8(+) T cells that was reversed upon cotreatment with CTLA-4-Ig.

191 K1/2 in AML cells, which was not affected by cotreatment with CXCL12.

192 Importantly, cotreatment with dexamethasone (Dex) could not efficient

193 in GC-resistant T-ALL cells, and remarkably, cotreatment with dexamethasone is able to reverse GC res

194 reased PARP activity in thymus and liver, as cotreatment with dioxin and the PARP inhibitor PJ34 incr

195 Furthermore, cotreatment with DNA replication inhibitor aphidicolin a

196 ts that the oxazolidine forms in situ, since cotreatment with doxorubicin and formaldehyde is highly

197 he lead molecule in the sulfamide series, in cotreatment with doxorubicin, demonstrated a chemosensit

198 ancer cells and render others susceptible to cotreatment with drugs and irradiation, with little or n

199 mpared with treatment with each agent alone, cotreatment with DZNep and the pan-histone deacetylase i

200 cancer cells were significantly lower after cotreatment with E plus TCDD than after treatment with E

201 Cotreatment with either fulvestrant or anastrazole compl

202 roprotection was substantially attenuated by cotreatment with either mevalonate or cholesterol and wa

203 he loss of CYP3A4 protein was accelerated by cotreatment with either proteasome or NF-kappaB inhibito

204 nucleus without endosomal entrapment because cotreatment with endosome-disrupting agent had no effect

205 Cotreatment with epigenetic-modulating drugs and checkpo

206 combined inhibitors and largely prevented by cotreatment with exogenous polyamines.

207 d interleukin-8 protein detectable following cotreatment with flagellin and Stx2.

208 d resistance to apoptosis can be overcome by cotreatment with Flavopiridol, which promotes survivin d

209 ShPTEN gland development were attenuated by cotreatment with GW9662, a PPARgamma antagonist.

210 Cotreatment with HA14-1, a nonpeptidic ligand that can b

211 This adaptation was prevented by cotreatment with hormone therapies or PI3K inhibitors, w

212 rantly overexpress functional ABCG2 but that cotreatment with IM and an ABCG2 inhibitor does not pote

213 However, cotreatment with inhibitors of mitochondrial oxidative p

214 Notably, cotreatment with inhibitors of the proteasome or the cyc

215 isomycin-induced amnesia was abolished after cotreatment with JNKs selective inhibitor sp600125 witho

216 Cotreatment with KNK437, a benzylidine lactam inhibitor

217 rted by Bcl-2 overexpression was reversed by cotreatment with LAQ824 and Apo-2L/TRAIL.

218 Significantly, cotreatment with LAQ824 increased Apo-2L/TRAIL-induced a

219 Cotreatment with LAQ824 increased imatinib mesylate-indu

220 Finally, cotreatment with LBH589 and 17-AAG also induced more apo

221 Cotreatment with LBH589 and 17-AAG exerted synergistic a

222 Cotreatment with LBH589 and AMN107 exerted synergistic a

223 Thus, cotreatment with LBH589 and AMN107 is active against cul

224 In the present study, we show that cotreatment with leptin and IGF-I significantly increase

225 f this tolerant state by ECP was obviated by cotreatment with lipopolysaccharide, suggesting that the

226 ion of 1alpha,25(OH)2D3 can be 'restored' by cotreatment with low doses of HDAC inhibitors such as tr

227 acellular permeability, which was blocked by cotreatment with LPA, but not LPA1 knockdown cells.

228 Lastly, cotreatment with LY blocked SB-mediated induction of p21

229 Cotreatment with MEK1/2 inhibitors increased the associa

230 Cotreatment with mevalonate inhibited the beneficial act

231 Cotreatment with mevalonate was used to assess the depen

232 Lovastatin-induced effects were reversed by cotreatment with mevalonolactone or geranylgeranyl-pyrop

233 red with all other treatment groups, whereas cotreatment with mTOR inhibitors preserved normal fertil

234 Destabilization of this conformation by cotreatment with muOR and deltaOR ligands leads to a swi

235 ytes, an effect that could be antagonized by cotreatment with muscarine.

236 Cotreatment with N-benzoyloxycarbonyl-(Z)-Leu-Leu-leucin

237 reduced with BSO treatment and restored with cotreatment with NAC or l-cysteine.

238 R1 expression (P<0.05), which was negated by cotreatment with nAChRalpha-7 antagonist.

239 Moreover, under basal conditions, cotreatment with PF-04957325 plus rolipram, a PDE4-selec

240 In contrast, cotreatment with phenformin, an inhibitor of complex I o

241 o short-term NMBA treatment and modulated by cotreatment with phenylethyl isothiocyanate (PEITC).

242 y arise in the clinic yet can be overcome by cotreatment with PI3K/AKT inhibitors.

243 Cotreatment with previously identified ellipticine and p

244 actor production, which could be reversed by cotreatment with prostaglandin E(2).

245 However, cotreatment with proteasome inhibitors fully restores th

246 Compared with each agent alone, cotreatment with PS and CXCR4 antagonist AMD3100 or FC-1

247 Cotreatment with PS and TG101209 further depleted JAK/ST

248 e association of eIF-4E with eIF-4G, whereas cotreatment with purvalanol A inhibited the association

249 rin in the podocytes, which was prevented by cotreatment with pyrintegrin.

250 RA alone had no effect on p53-NRD activity, cotreatment with RA and the histone deacetylase inhibito

251 Cotreatment with rapamycin and trichothecenes reduced RO

252 Treatment with VEGF and cotreatment with Rb1 and VEGF showed that this Rb1-induc

253 Cotreatment with selective blockers of L-, N-, and P/Q-t

254 Cotreatment with sildenafil enhanced DOX-induced apoptos

255 Cotreatment with specific P-gp inhibitor PSC833 reversed

256 Cotreatment with Stx2 and flagellin results in a synergi

257 Cotreatment with TG101209 and PS exerted greater cytotox

258 BRCA-1 transcription are counteracted by (a) cotreatment with the AhR antagonist 3'-methoxy-4'-nitrof

259 These effects were reversed by cotreatment with the Akt inhibitors perifosine and GSK69

260 in II-induced hypertension was attenuated by cotreatment with the alphaAnalogue (50 nmol.kg(-1).d(-1)

261 These IGF-1 actions, which may be blocked by cotreatment with the anti-IGF-1 antibody, were accompani

262 bacterial CDDL expression, and abrogated by cotreatment with the antibiotic ciprofloxacin.

263 e effects are significantly attenuated after cotreatment with the antioxidant GSH.

264 Cotreatment with the autophagy inhibitor chloroquine blo

265 Accordingly, cotreatment with the autophagy inhibitor chloroquine inc

266 Cotreatment with the Bcl-2/Bcl-x(L) antagonist ABT-737 d

267 Cotreatment with the BMP antagonist noggin or the NADPH

268 Cotreatment with the BMP-2 antagonist DMH1 limits, but d

269 Cotreatment with the caspase-3 inhibitor Z-VAD-FMK abrog

270 uamous cell carcinoma in a mouse model using cotreatment with the compound and the carcinogen.

271 Cotreatment with the diuretic furosemide in wild-type mi

272 was independent of CYP3A4 and was negated by cotreatment with the drug efflux transporter inhibitor e

273 Cotreatment with the ER antagonist tamoxifen completely

274 Cotreatment with the GLP-1 receptor agonist exendin-4 re

275 R2(+) cells, knockdown of HER3 with siRNA or cotreatment with the HER2 inhibitors trastuzumab or lapa

276 t the antitumor effects of AT are blocked by cotreatment with the HMG-CoA reductase product mevalonat

277 ent hepatocytes incubated with omega-3 PUFA, cotreatment with the iron chelator desferrioxamine, an i

278 ith elevated OxPhos could be resensitized by cotreatment with the mTORC1/2 inhibitor AZD8055, whereas

279 vo and that this effect could be reversed by cotreatment with the OAT6 inhibitor probenecid.

280 rylation and activity, which were blocked by cotreatment with the PI3 kinase inhibitor wortmannin.

281 nists was significantly down-regulated after cotreatment with the PPARgamma antagonist GW9662.

282 Furthermore, cotreatment with the proteasome inhibitor N-benzoyloxyca

283 Cotreatment with the prototypical pregnane X receptor ac

284 s, which could not, however, be prevented by cotreatment with the selective CypD inhibitor, Debio 025

285 This protection was abolished by cotreatment with the SERCA inhibitor cyclopiazonic acid.

286 Cotreatment with the Src-family kinase inhibitor PP2 pre

287 Moreover, skin inflammation was reduced by cotreatment with the TNFalpha signaling inhibitor, etane

288 Cotreatment with these interventions either markedly att

289 and malignant cell death can be achieved by cotreatment with TNF-alpha and a mimetic of second mitoc

290 Cotreatment with TNF-alpha augmented the formation and a

291 Cotreatment with tPA resulted in greater intratumoral pe

292 e non-narcotic clinical analgesics utilizing cotreatment with ultra-low-dose rolipram plus ultra-low-

293 The effects of cotreatment with various concentrations of SA and JA wer

294 Cotreatment with VEGF-trap completely sequestered free V

295 f 1-analogues is likely MDR-mediated because cotreatment with verapamil, a P-gp inhibitor, partially

296 A cotreatment with vitamin C (1 mM) efficiently inhibited

297 ency was effectively reduced consequent to a cotreatment with vitamin C.

298 In cotreatments with IFNgamma, DIM produced an additive act

299 Pretreatment, but not cotreatment, with interferon attenuators valproate, Jak1

300 sfer of EphA2-specific CD8+ T cells, 17-DMAG cotreatment yielded a superior tumor therapeutic regimen